6 completed, 3 unknown, 2 terminated. 7 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Terminated 2, Unknown 2 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Unknown 1 |
Follow Antisoma Research: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) Amonafide + cytarabine - Acute Myeloid Leukemia | Phase 2 | Unknown | Antisoma Research | 20 | 2010-01-01 | 2011-01-17 |
| A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia AS1411, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Terminated | Antisoma Research | 90 | 2010-01-01 | 2011-02-02 |
| Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer AS1402, Letrozole - Breast Carcinoma | Phase 2 | Terminated | Antisoma Research | 110 | 2008-09-01 | 2009-08-10 |
| A Phase II Study of AS1411 in Renal Cell Carcinoma AS1411 - Metastatic Renal Cell Carcinoma | Phase 2 | Unknown | Antisoma Research | 30 | 2008-08-01 | 2009-09-25 |
| Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma AS1409 - Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma | Phase 1 | Completed | Antisoma Research | 13 | 2008-01-01 | 2009-08-25 |
| Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia AS1411 - Leukemia, Myeloid | Phase 2 | Completed | Antisoma Research | 70 | 2007-07-01 | 2009-09-25 |
| Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study Daunorubicin and Cytarabine, Amonafide and Cytarabine - Secondary Acute Myeloid Leukemia (Secondary AML, sAML) | Phase 3 | Unknown | Antisoma Research | 420 | 2007-06-01 | 2010-10-13 |
| Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer AS1404 (DMXAA) - Prostate Cancer | Phase 2 | Completed | Antisoma Research | 70 | 2005-05-01 | 2009-01-30 |
| Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer DMXAA in combination with carboplatin and paclitaxel - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Antisoma Research | 105 | 2004-09-01 | 2009-01-30 |
| Study of AS1411 in Advanced Solid Tumours AS1411 - Advanced Solid Tumors | Phase 1 | Completed | Antisoma Research | 30 | 2003-09-01 | 2009-04-15 |
| Phase I Safety Study of DMXAA in Refractory Tumors DMXAA - Refractory Tumors | Phase 1 | Completed | Antisoma Research | 15 | 2003-05-01 | 2009-03-05 |
Carcinoma, Renal Cell (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Acute Disease (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Kidney Neoplasms (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Melanoma (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1)
AGRO 100 (4) · Cytarabine (3) · vadimezan (3) · amonafide (2) · AS1409 protein (1) · Carboplatin (1) · Daunorubicin (1) · Letrozole (1) · Paclitaxel (1) · epitumomab (1)
United States (6) · New Zealand (3) · Australia (2) · Russia (2) · Taiwan (2) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · Ecuador (1) · Estonia (1)
Mark McKeage (2) · Gary Acton, MA MBBS MRCP (1) · Greg Smith, MD (1) · Harry Drabkin, MD (1) · James Spicer, MD (1) · Mark Jeffery (1) · Michael Jameson (1) · Nuhad K Ibrahim, MD FACP (1) · Rob Stuart, MD (1) · Roberto Pili, MD (1)
PMID 16551862, PMID 17356709, PMID 19387077, PMID 21447719, PMID 21878535, PMID 22263047, PMID 24242861, PMID 25550361, PMID 25732165, PMID 40443562